Evommune (EVMN) Total Non-Current Liabilities (2024 - 2025)
Evommune's (EVMN) quarterly Total Non-Current Liabilities came in at $10.4 million in Q3 2025, down 62.77% on a QoQ basis from $28.0 million in Q4 2024.
Evommune (EVMN) Total Non-Current Liabilities (2024 - 2025) Analysis & Trends
Evommune (EVMN) has 2 years of Total Non-Current Liabilities data on file, last reported at $10.4 million in Q3 2025.
- On a quarterly basis, Total Non-Current Liabilities changed N/A year-over-year to $10.4 million in Q3 2025; TTM through Sep 2025 was $10.4 million, a N/A change from a year earlier, with the FY2024 full-year figure at $28.0 million, changed N/A from the prior year.
- Total Non-Current Liabilities for Q3 2025 stood at $10.4 million, down from $28.0 million in the prior quarter.
- Over the last five years, Total Non-Current Liabilities for EVMN reached as high as $28.0 million in Q4 2024 and fell as low as $10.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 4.45 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 110.28 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.98 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 949,738.67 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 5.87 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 7.32 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 40.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 746.94 Mn |
| 10 | Evommune | 381.48 Mn | 170.02 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 10.42 Mn |
| Dec 31, 2024 | 27.98 Mn |